Pharmalytics Group Information

We partner with pharma, biotech, and medical device companies to anticipate evidence challenges, generate rigorous clinical, economic, and outcomes evidence, and build defensible value propositions for health technology assessment and reimbursement. Our work spans early evidence strategy, literature reviews, indirect treatment comparisons, real-world evidence, health economic modelling, reimbursement submissions, and post-launch evidence evolution. We combine methodological depth, analytical discipline, and a practical understanding of how decision-makers evaluate evidence. Every program is designed to be robust, transparent, coherent, and aligned with the relevant jurisdiction and decision context. Our team brings together health economists, statisticians, evidence synthesis specialists, clinicians, data scientists, and market access advisors. We support clients across North America and Europe, from early planning through submission, defense, reassessment, and lifecycle management.